The effect of zinc supplementation on fatty liver

Effect of zinc supplementation on serum zinc status, lipid profile, liver enzymes (ALT, AST), insulin resistance, inflammatory markers and oxidative stress in non-alcoholic fatty liver patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191015045113N1

Enrollment

Registered

2019-12-08

Start date

2018-09-23

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Alcoholic Fatty Liver Disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Twenty - five patients with ultrasound - confirmed non - alcoholic fatty liver disease received a coated capsule containing 30 mg of Nature Made made at the Faculty

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: -Attention to fatty liver confirmed by ultrasound - Ages between 18 and 70 years -Not consuming alcoholic beverages - Lack of other liver diseases such as viral hepatitis, liver cirrhosis, Wilson's disease ... - Lack of parenteral nutrition -No diseases that affect the bile and bile ducts - No severe weight loss 6 months ago -Not taking medications that cause fatty liver (methotrexate, tamoxifen, valproate, etc.) -No pregnancy and breastfeeding - Lack of serum ALT levels more than 10 times the limit - No chemotherapy during the past year -Not taking any supplements containing zinc

Exclusion criteria

Exclusion criteria: People who have done chemotherapy over the past year People with any biliary disease People taking any supplements and drugs containing zinc People who have had severe weight loss in the past 6 month People taking any form of fatty liver medication

Design outcomes

Primary

Measure	Time frame
Serum zinc. Timepoint: 8 weeks. Method of measurement: Blood sampling.;Insulin resistance. Timepoint: 8 weeks. Method of measurement: Blood sampling.;ALT. Timepoint: 8 Week. Method of measurement: blood sample.	—

Secondary

Measure	Time frame
Fasting blood sugar. Timepoint: 8 week. Method of measurement: blood sample.;Serum total cholesterol. Timepoint: 8 week. Method of measurement: blood sample.;Serum triglyceride. Timepoint: 8 Week. Method of measurement: blood sample.;MDA. Timepoint: 8 week. Method of measurement: blood sample.;Total Antioxidant Capacity (TAC). Timepoint: 8 week. Method of measurement: blood sample.;Hs-CRP. Timepoint: 8 week. Method of measurement: blood sample.	—

Measure

Time frame

Fasting blood sugar. Timepoint: 8 week. Method of measurement: blood sample.;Serum total cholesterol. Timepoint: 8 week. Method of measurement: blood sample.;Serum triglyceride. Timepoint: 8 Week. Method of measurement: blood sample.;MDA. Timepoint: 8 week. Method of measurement: blood sample.;Total Antioxidant Capacity (TAC). Timepoint: 8 week. Method of measurement: blood sample.;Hs-CRP. Timepoint: 8 week. Method of measurement: blood sample.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Mohammad Amin Rezaei

Shiraz University of Medical Sciences

seyedamin.rezaei69@gmail.com+98 74 3232 2519

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 9, 2026